Home Stock

Stock Research: J. B. Chemicals & Pharmaceuticals

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

J. B. Chemicals & Pharmaceuticals

BSE:506943 INE572A01028
79
  • Value
    33
  • Growth
    66
  • Safety
    Safety
    76
  • Combined
    61
  • Sentiment
    96
  • 360° View
    360° View
    79
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

J.B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. It specializes in gastroenterology, hypertension, dermatology, nephrology, respiratory, virology, diabetes, and nicotine replacement therapy (NRT), manufacturing pharmaceutical formulations, herbal remedies, and APIs. Brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. The company has a direct presence in Russia and South Africa, with distributor relationships in the United States, Asia, Africa, and Latin America. In the last fiscal year, the company had a market cap of $3005 millions, profits of $292 millions, revenue of $459 millions, and 5517 employees.

more
Strongest Rank Price vs. Book (P/B)
Weakest Rank Sentiment
Country India
Industry Pharmaceuticals
Size Small
Website jbcpl.com
Index
J. B. Chemicals & Pharmaceuticals stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 18-Dec-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
33 25 23 43
Growth
66 81 85 33
Safety
Safety
76 27 17 100
Sentiment
96 71 76 84
360° View
360° View
79 47 44 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
83 87 70 97
Opinions Change
50 14 40 50
Pro Holdings
n/a 68 27 63
Market Pulse
93 86 93 25
Sentiment
96 71 76 84
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
33 25 23 43
Growth
66 81 85 33
Safety Safety
76 27 17 100
Combined
61 27 23 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
34 33 30 49
Price vs. Earnings (P/E)
31 31 27 41
Price vs. Book (P/B)
28 24 28 50
Dividend Yield
55 28 45 39
Value
33 25 23 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
70 72 70 70
Profit Growth
61 67 78 10
Capital Growth
42 84 19 1
Stock Returns
55 53 89 91
Growth
66 81 85 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
90 44 36 84
Refinancing
33 22 28 64
Liquidity
79 44 40 90
Safety Safety
76 27 17 100

Similar Stocks

Discover high‑ranked alternatives to J. B. Chemicals & Pharmaceuticals and broaden your portfolio horizons.

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Fleury

BOVESPA:FLRY3
Country: Brazil
Industry: Health Care Services
Size: Medium
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Bosch

BSE:500530
Country: India
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews